Genotype-Guided SSRI Prescribing tied to Delayed but Meaningful Benefit: JAMA
USA: Researchers have found in a randomized clinical trial that genotype-guided selection of SSRIs did not improve depression symptom control at 3 months compared to usual care. However, it was associated with higher remission rates at 6 months, suggesting a potential long-term clinical advantage. These results highlight the need for further research focusing on the durability and sustained impact of genotype-guided prescribing in depression management.
The findings are from a study published in JAMA Network Open by Kathryn V. Blake, Center for Pharmacogenomics and Translational Research, Nemours Children’s Health, Jacksonville, Florida, and colleagues.
Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly prescribed medications for depression. Since genetic differences can influence how patients metabolize these drugs, researchers aimed to evaluate whether pharmacogenetic-guided prescribing could improve treatment outcomes in routine clinical practice.
To investigate this, the researchers conducted the ADOPT PGx (A Depression and Opioid Pragmatic Trial in Pharmacogenetics) randomized clinical trial across primary care, psychiatry, and family medicine clinics in the United States between August 2021 and April 2024. The study enrolled patients aged 8 years and older who had experienced depression symptoms for at least 3 months.
Participants were randomly assigned either to genotype-guided SSRI prescribing or to standard treatment. The investigators focused particularly on patients with actionable drug metabolism phenotypes, meaning individuals whose genetic profiles suggested that medication selection or dose adjustment may be beneficial according to established pharmacogenetic guidelines.
The trial revealed the following findings:
- The trial included 1,460 participants, comprising 1,239 adults and 221 children.
- Nearly 47.4% of participants had actionable pharmacogenetic phenotypes that could influence SSRI prescribing decisions.
- More than two-thirds of patients with actionable phenotypes had experienced depressive symptoms for longer than two years at baseline.
- Most participants were already receiving pharmacologic treatment for depression at study enrollment.
- At 3 months, genotype-guided SSRI prescribing did not show a significant advantage over usual care in improving depression symptoms.
- Changes in PROMIS depression scores and PHQ-8 scores were similar between the genotype-guided and standard care groups.
- The burden of SSRI-related adverse effects also did not differ significantly between the two groups at 3 months.
- At 6 months, patients receiving genotype-guided prescribing showed higher depression remission rates compared with those receiving usual care.
- Nearly half of the participants in the genotype-guided group achieved remission, compared with just under 40% in the standard care group.
The authors noted limitations, including variability in clinical practices across sites, incomplete pharmacogenetically concordant therapy in some patients, and delays in treatment changes and follow-up during the COVID-19 pandemic.
The authors concluded that genotype-guided SSRI prescribing did not improve short-term depression symptom control but may provide longer-term clinical benefits. They emphasized that future studies should further explore the durability, timing, and sustained effects of pharmacogenetic-guided antidepressant treatment strategies.
Reference:
Blake KV, Hines LJ, Liu M, et al. Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(5):e2610609. doi:10.1001/jamanetworkopen.2026.10609
Next Story